195 results about "Continuous glucose monitoring" patented technology

A medical device for predicting a user's future glycemic state includes a memory module, a processor module and a user alert module. The memory module is configured to receive and store a plurality of glucose concentrations as a function of time that were generated by a user's use of a continuous glucose monitor. The processor module is configured to derive first and second glucose prediction equations that are fits to the plurality of glucose concentrations stored in the memory module with the fits being based on first and second mathematical models, respectively. The processor module is also configured to calculate first and second predicted glucose concentrations at a future time using the first and second glucose prediction equations, respectively, and to also calculate an average predicted glucose concentration and a merit index based on the first and second predicted glucose calculations. The processor module is further configured to input the plurality of glucose concentrations as a function of time, the average predicted glucose concentration and the merit index into a trained model (e.g., a Hidden Markov Model) that outputs a set of glucose concentration probabilities for the future time and to then predict the user's future glycemic state based on the set of glucose concentration probabilities. The user alert module is configured to alert the user in a manner dependent on the predicted user's future glycemic state.

A system and method for providing optimal insulin injections to a subject, using a controller, a continuous glucose monitor, and an insulin delivery unit is disclosed. The controller possesses a discrete-time, linear model predictive control law, means for sending information to the insulin delivery unit, and means for receiving information from the CGM. The control law implemented is derived from a discrete-time model of glucose insulin dynamics and an aggressiveness parameter. The result is that using only glucose measurements obtained from sensor readings and, prior values of external insulin infusion and meal and exercise announcement the optimal insulin injection necessary to safely regulate blood glucose can be calculated.

A method and apparatus for substance monitoring. One application is an easy to handle continuous glucose monitor using a group of hollow out-of-plane silicon microneedles to sample substances in interstitial fluid from the epidermal skin layer. The glucose of the interstitial fluid permeates a dialysis membrane and reaches a sensor. Using MEMS technology, for example, allows well-established batch fabrication at low cost.

Embodiments of the present invention provide a new system and methods for monitoring blood glucose concentration. A user of a continuous glucose monitor may program upper and lower blood glucose notification thresholds to fluctuate over time in order to facilitate management of the short-term effects of food consumption, insulin delivery aberrations, physical activity, emotions, and unforeseen circumstances.

The invention provides a transdermal analyte sensing device and an installation method thereof. The percutaneous analyte sensing device includes a medical adhesive plaster, a probe base with first, second and third installation structures on it; used for combining the probe body, the probe installer and the emitter. The probe installer includes an instant ejection-recovery mechanism and a release button, which can instantly complete the ejection and recovery actions of the guide needle without manual operation. After the probe body of the present invention is installed, the probe installer can be easily removed, and the transmitter can be easily installed and removed. The transdermal analyte sensing device of the present invention is also provided with a protective cover that can be combined with the probe base and the probe mount. The transdermal analyte sensing device of the present invention is small in size, easy to wear, simple and safe to install and operate, and provides a perfect solution for users to realize continuous blood sugar monitoring by themselves.

A device may be implanted subcutaneously with an attached catheter inserted within, e.g., the peritoneal cavity of a subject. The catheter and / or device may also be inserted into another space, e.g., subcutaneous, vascular, peritoneal, cerebrospinal, pleural spaces, etc. The peritoneal fluid which normally collects and / or flows through the peritoneal cavity may be detected by the catheter and analyzed via the device to detect the concentration of glucose within the fluid.

An inserter assembly for continuous glucose monitoring with medication delivery capability where the assembly has a deployment button containing a needle deployment mechanism having a sharp held in a pre-release position, a housing body in which the deployment button is movably received within a top end of the housing body, the housing body having a sensor deployment assembly containing a lumen and a sensor disposed within the lumen and extending out of the lumen to a circuit board that is part of the sensor deployment assembly, the sensor deployment assembly matingly connected to the sharp where the sharp extends beyond the sensor deployment assembly and contains the sensor not fixedly attached to the sharp, and a sensor housing releasably received within a lower end of the housing body, the sharp extending into a sensor deployment assembly recess within the sensor housing and directly above a sensor opening in a bottom of the sensor housing.

A method and apparatus for substance monitoring. One application is an easy to handle continuous glucose monitor using a group of hollow out-of-plane silicon microneedles to sample substances in interstitial fluid from the epidermal skin layer. The glucose of the interstitial fluid permeates a dialysis membrane and reaches a sensor. Using MEMS technology, for example, allows well-established batch fabrication at low cost.

The use of electrical impedance spectroscopy to adjust calibration settings in an in vivo monitoring system, such as an in vivo continuous glucose monitoring sensor. The adjustments can compensate for the condition of the sensor membrane in vivo.

A system and method for reducing the number of hypoglycemic alarms presented to a user is presented. The system and methods include use of model based state estimation and variable-delayed threshold values to balance the risk of not presenting an alarm caused by an actual hypoglycemic state with the presentation of alarms caused by artifacts in the signals produced by a continuous glucose monitor.

A passive sensing continuous glucose monitoring system and method of use thereof. The system includes a passive antenna formed of biocompatible silicon carbide (SiC), modeled to a desired frequency, which is permanently implanted subcutaneously. The system further includes an external-to-the-body transmitting antenna to detect changes in the blood glucose level by sending a radio signal at the frequency of the implanted passive antenna into the body. This signal is received and reflected by the passive antenna, and the reflected signal is then received at an external-to-the-body receiving antenna. Changes in the glucose level lead to modifications in the signal and can be used to determine the blood glucose level externally.